Live-cell immunization (LC-I) is a powerful technique for generating mAbs, particularly when targeting membrane proteins or protein complexes that are difficult to get the immune responses. It is especially effective against intractable targets, including conformational, native epitopes, complex post-translational modifications (PTMs), aberrant isoforms, and multimeric complexes. The conventional live-cell immunization methods are labor-intensive and often generate numerous false positive or non-specific antibodies. 

Our live-cell immunization (LC-I) and live-cell high-throughput screening (LC-HTS) platforms overcome these limitations with our "know-how" technologies, which enable the discovery of First-in-Class (FIC) antibodies against challenging and previously undruggable receptors. By incorporating a proprietary counter-screening technology, we ensure that the generated antibodies are highly specific, selectively binding to novel conformational epitopes that are overexpressed in cancer cells but minimally or not expressed in normal tissues. This opens new avenues for targeted therapies in areas of unmet medical need.